Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to SEC filings for Park Ha Biological Technology Co., Ltd. (Nasdaq: BYAH), a company engaged, according to available information, in developing its private skincare label and providing skincare and cosmetic products under the Park Ha brand in China. The company’s operating subsidiaries develop proprietary beauty products and offer complimentary after-sales beauty services in physical stores, alongside direct skincare product sales and franchise alliances promotions.
Although no specific SEC filings are listed in the available data, this section is designed to aggregate regulatory documents filed by Park Ha Biological Technology Co., Ltd. with the U.S. Securities and Exchange Commission. These filings may include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other disclosure documents, when applicable. Such materials can provide details about the company’s business activities, risk factors, and other aspects of its operations related to the Park Ha skincare and cosmetic products business.
On the Stock Titan platform, SEC filings are paired with AI-powered summaries that explain the key points of each document in accessible language. Real-time updates from the SEC’s EDGAR system help surface new filings as they become available. Users can review core reports such as 10-K and 10-Q, as well as transaction-related filings like Form 4 for insider share dealings, with AI-generated highlights that point out important sections and changes.
For investors analyzing Park Ha Biological Technology Co., Ltd., this page offers a structured way to review the company’s regulatory history and disclosures in connection with its Nasdaq listing under the symbol BYAH.
Park Ha Biological Technology Co., Ltd. filed a Form F-3 shelf registration to offer up to $300,000,000 of Class A ordinary shares and various securities, to be sold from time to time under prospectus supplements. The company warns of PRC regulatory, cybersecurity and HFCAA/PCAOB risks and discloses prior financings, corporate restructurings, and a January 28, 2026 follow-on unit offering.
Park Ha Biological Technology Co., Ltd. director Shan Yanan has filed an initial Form 3 insider ownership report. The available data shows no reported transactions or derivative positions, and no share holdings are detailed in this snapshot of the filing.
Park Ha Biological Technology Co., Ltd. CTO Li Xinyu has reported initial ownership on a Form 3. The filing shows 937.5 Class A Ordinary Shares are held indirectly through Changxin International Limited Partnership, where Ms. Li is a limited partner. A footnote states these shares were acquired on October 11, 2022.
Park Ha Biological Technology Co., Ltd. director Yu Xiaozhong filed an initial Form 3 to report insider status with respect to BYAH. The filing lists Yu as a director and confirms that, at the time of this report, no insider transactions or derivative positions are reported.
Park Ha Biological Technology Co., Ltd. filed an initial insider ownership report for CFO Zhu Xiaoyan. The filing shows 2,500 Class A Ordinary Shares held indirectly through Changxin International Limited Partnership. A footnote states these 2,500 Class A Ordinary Shares were acquired on October 11, 2022, with Ms. Zhu described as a limited partner of that partnership.
Park Ha Biological Technology Co., Ltd. director and CEO Zhang Xiaoqiu filed an initial Form 3 reporting her beneficial ownership in the company. She is identified as a director, officer and ten percent owner.
The filing shows indirect ownership of 381,000 Class B Ordinary Shares, held through Xiaoqiu Holdings Limited, where she is the sole shareholder and director. A footnote states that these 381,000 Class B Ordinary Shares were acquired on October 11, 2022, and the Form 3 records this existing position rather than reporting a new market transaction.
Park Ha Biological Technology Co., Ltd. director Sheng Qixiong has filed an initial statement of beneficial ownership as a reporting person. This Form 3 lists him as a director but shows no reported transactions, acquisitions, or derivative positions at the time of the filing.
Park Ha Biological Technology Co., Ltd. reported that Li Wang resigned as a director of the company, effective March 16, 2026. The company states that her resignation was not due to any disagreement with its operations, policies, or procedures.
The report is signed by Chief Executive Officer and Chairperson Xiaoqiu Zhang, indicating the change has been formally approved and acknowledged at the highest leadership level.
Park Ha Biological Technology Co., Ltd. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company that its Class A ordinary shares closed at or above $1.00 per share for 10 consecutive business days from February 20 through March 5, 2026.
Meeting this threshold satisfies Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, and Nasdaq has closed the matter. This removes the immediate risk that the company’s shares could be delisted for bid-price non-compliance.
Park Ha Biological Technology Co., Ltd. files its annual Form 20-F, outlining operations conducted entirely through PRC subsidiaries in the beauty and skincare industry and detailing extensive China-related regulatory risks.
The company highlights cybersecurity, data, CSRC filing and HFCAA audit-inspection risks that could ultimately lead to trading prohibitions or delisting, as well as controls on cross-border cash transfers and dividend payments. As of October 31, 2025, there were 296,488 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding.
The filing also describes reliance on third-party manufacturers’ formulas, a highly competitive beauty market, dependence on a few major customers and franchise expansion, and structural risks tied to variable interest entities used to control certain beauty salons in China.